DRUG DIVERSION LAW REQUIRES UNAUTHORIZED DISTRIBUTORS TO DISCLOSE
DRUG DIVERSION LAW REQUIRES UNAUTHORIZED DISTRIBUTORS TO DISCLOSE their product sources and chain of distribution to customers, FDA Associate Commissioner for Legislative Affairs Hugh Cannon reiterated in a May 22 letter to Sen. Graham (D-Fla.). "The intent of the law [the 1987 Prescription Drug Marketing Act] is to require an unauthorized distributor to disclose, in a statement to its customers, identifying information regarding all previous sales of a prescription drug product," Cannon said. Graham had written FDA April 20 on behalf of Deerfield Beach, Fla.-based distributor United Wholesale, which says it is "adversely affected" by the agency's reading of the drug diversion law. "If the proposed regulations require us to reveal the sources of our product to our customers, it would permit them in most instances to buy directly from our vendors, effectively putting us and other wholesale distributors out of business," United Wholesale President Alan Peller protested in a letter to Graham. Calling the law as currently interpreted anticompetitive, United Wholesale proposed that second-hand distributors disclose their sources to FDA, rather than to customers. A similar objection to required disclosure of secondary-source wholesalers' product sources was registered last year by the American Association of Pharmaceutical Distributors ("The Pink Sheet" May 22, 1989, p. 5). United Wholesale is a member of AAPD. The association was formed to represent the interests of secondary-source distributors after passage of the drug diversion law. AAPD had elicited letters supporting a deletion of the disclosure requirement from nine senators on the Senate Finance Committee, which had jurisdiction over the diversion legislation. FDA has not changed its interpretation of the policy, according to the agency's letter to Graham.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth